Benzinga's Small Cap Movers for Wednesday November 28, 2012
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
Shares of Vermillion (NASDAQ: VRML), the Austin, TX diagnostic testing company, rose 39% Wednesday on 52 times average volume and then rose 9% after-hours.
Gynecologic Oncology, the medical journal of the Society for Gynecologic Oncology, has published the second prospective clinical study of OVA1 which demonstrated the positive performance of the multi-biomarker test in the triage of early-stage ovarian cancer.
Vermillion had reported positive top-line results of the study in July. Referred to as "OVA500," the study confirms and extends the findings of the first OVA1 pivotal study published last year in Obstetrics & Gynecology by Dr. Fred Ueland of the University of Kentucky.
The OVA500 results were published online by Gynecologic Oncology on November 22 in the article, "Ovarian Malignancy Risk Stratification of the Adnexal Mass Using a Multivariate Index Assay." The article was authored by Dr. Robert E. Bristow, the director of Gynecologic Oncology Services at UC Irvine Healthcare and former director of gynecologic oncology at Johns Hopkins.
Vermillion closed at $1.66 on Wednesday.
Shares of iGo (NASDAQ: IGOI), the Scottsdale, AZ provider of power solutions for laptop computers and electronic mobile devices, rose 22% Wednesday on 11 times average volume.
A positive Seeking Alpha article published Wednesday, was most likely the cause of the rise in iGo.
iGo closed at $0.32 on Wednesday.
Shares of DragonWave (NASDAQ: DRWI), the Ottawa, ON provider of high-capacity packet microwave solutions, rose 19% Wednesday on 3.5 times average volume.
DragonWave announced Tuesday it had signed a new contract with its existing customer WireIE valued at approximately $1 million in the first year.
DragonWave closed at $2.14 on Wednesday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.